Hassaniazad, Mehdi
Inchehsablagh, Behnaz Rahnama
Kamali, Hossein
Tousi, Abdolali
Eftekhar, Ebrahim
Jaafari, Mahmoud Reza
Fathalipour, Mohammad
Nikoofal-Sahlabadi, Sara
Gouklani, Hamed
Alizade, Hesam
Nikpoor, Amin Reza http://orcid.org/0000-0001-5619-8771
Funding for this research was provided by:
Hormozgan University of Medical Sciences (990126)
Article History
Received: 5 October 2020
Accepted: 16 October 2020
First Online: 22 October 2020
Ethics approval and consent to participate
: The present clinical trial was approved by the Ethics Committee of Hormozgan University of Medical Sciences (number: HUMS.REC.1399.174) on June 10, 2020. We declare that this trial has received ethical approval from the appropriate ethical committee as described above. Prior to entering the study, all participants in the study will be fully informed about the study, and will sign an informed consent.
: Not applicable.
: Prof. Mahmoud Reza Jaafari founded Nano Sina Company (ENSC), a Nano pharmaceutical company, which provided the curcumin-containing Nanomicelles and is a co-author in the trial. Prof. Jaafari helped in the design of study, selection of dose and duration of consumption of SinaCurcumin, and also writing and final checking of the manuscript.The other authors declare that they have no competing interests.